LECO Supports New West Coast Metabolomics Center
St. Joseph, Mich. February 13, 2013—LECO Corporation has announced its support of the West Coast Metabolomics Center, a new high-tech consortium of research and service laboratories housed within the University of California, Davis, Genome Center.
As part of an agreement with LECO, the West Coast Metabolomics Center will receive access to the LECO Citius™ LC-HRT (High Resolution TOFMS) for applied research in metabolomics that will help scientists better understand and develop more effective treatments for complex diseases like diabetes, cancer, and atherosclerosis. Designed for complex sample analysis, LECO’s HRT instrumentation provides acquisition speeds of up to 200 spectra/second, mass resolution up to 100,000 FWHM, and mass accuracy less than 1 ppm.
The new center is under the direction of Dr. Oliver Fiehn, professor of molecular and cellular biology at UC Davis. A worldwide leader in metabolomics, Dr. Fiehn has utilized LECO instruments to analyze more than 50,000 samples for more than 520 projects and 80 different species over the past seven years. The results have been the basis for many scientific papers, ranging from microbial products to plant and pre-clinical and clinical studies.
“LECO is known for its robust and sensitive instruments, and its great software capability for distinguishing closely eluting compounds,” said Dr. Fiehn. “We believe the Citius may solve urgent bottlenecks in metabolomics, specifically because in our field, we have highly complex mixtures of compounds!”
“This partnership demonstrates LECO’s renewed commitment to the advancement of metabolomics,” said Dr. Jeff Patrick, Director of Marketed Technology, LECO Separation Science. “We are honored that Dr. Fiehn and his team chose the Citius LC-HRT to be part of the West Coast Metabolomics Center, and we are excited about the implications their research will have on the treatment of certain diseases.”